In the News | Charles River
   
 
 
   
   

Similar or Better?
Pharma Magazine
July/August 2011

Follow the biosimilar pathway with reduced developmental costs, but low market share at a reduced price, or take the full development cost knowing that the product is more likely to reach the market in a form that will capture a potentially larger share of the indication market at a premium price? Which is better? The answers will tell us a great deal about the future of the biopharma industry.

Click here to read the full article from Pharma Magazine.

 

   
Discover the full range of Charles River Products and Services
The Source

For more information, contact us at:

1.877.CRIVER.1 (1.877.274.8371)
askcharlesriver@crl.com

view all

News & Events

view all
May 14 - New Models for Evaluating COPD or ...
May 11 - Expert Safety Testing to Accelerat...
Jun 17-Jun 20 -  Noordwijk aan Zee, the Netherlands - 19th MDO Meeting / 12th European ...
Jun 02-Jun 05 - Vancouver, British Columbia - CALAS
Jun 05-Jun 05 - King of Prussia, Pennsylvania - Assessment of Immunomodulation for Biol...
Jun 05-Jun 08 - Saint Germain sur l’Arbresle, France - Charles River LAL Seminar Series
view all
Scientist I Wilmington, MA
Manager International Tax Wilmington, MA

Charles River Laboratories, Inc.